Supplementary Figure 1: Dinaciclib potentiates cytotoxic effects of doxorubicin from A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
Year: 2023
Type: supplementary-materials
Abstract: MM.1S (A) and H929 (B) cell lines were treated with doxorubicin (DOX; 0‒160 nM) {plus minus} dinaciclib (SCH; 20 nM); viable cell number was assessed by WST-1 after 72h. Mean survival {plus minus} SEM is shown for 3 replicate experiments normalized to the untreated controls, and statistical comparisons were made by 2-tailed paired t-tests against SCH treatment alone (open bar, DOX = 0 nM), with the exception of SCH treatment, which was compared to its control treatment (i.e. filled vs. open bar, at DOX = 0 nM). *, **, *** and **** indicate p<0.05, 0.01, 0.001, and 0.0001, respectively.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362622666